Emens has developed innovative combination immunotherapies that incorporate cancer vaccines, immune checkpoint inhibitors and other immune modulators with standard and novel treatments for breast cancer. She plays a vital role in leading the effort to advance translational cancer immunotherapy at UPMC Hillman and was the first to show that a combination of immunotherapy and chemotherapy can extend the lives of women with triple negative breast cancer. Her research led to accelerated approval by the U.S. Food and Drug Administration
for this treatment to address one of the most aggressive forms of breast cancer.
The Holzer Fund, now in its third year, was established to honor Sy Holzer’s philanthropic work as the long-time president of PNC
and his many years of service as chair of the UPMC Hillman Cancer Center Council. The fund has been supported through leadership gifts made by many local and national individual funds, foundations and corporations. This award, once again, is being matched by the Stanley M. Marks Endowed Research Fund at UPMC Hillman Cancer Center.
Emens is the vice president/president-elect of the Society for Immunotherapy of Cancer. She also is a member of the American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, the Federation of Clinical Immunology Societies and the European Society for Medical Oncology. She has received multiple awards for research and clinical care, including a Stand Up to Cancer Laura Ziskin Prize in Translational Research, Castle Connolly Exceptional Women in Medicine, the Hillman Fellowship for Innovative Cancer Research and U.S. News and World Report Top Doctor (Top 1% in Nation).
PHOTO INFO: (click image for high-res version)
CAPTION: Leisha A. Emens, M.D., Ph.D., co-leader, Cancer Immunology and Immunotherapy Program and director of Translational Immunotherapy for the Women’s Cancer Research Center, UPMC Hillman Cancer Center.